K092894 · Eps Bio Technology Corp. · NBW · Feb 24, 2010 · Clinical Chemistry
Device Facts
Record ID
K092894
Device Name
EASYMAX V SELF MONITORING BLOOD GLUCOSE SYSTEM
Applicant
Eps Bio Technology Corp.
Product Code
NBW · Clinical Chemistry
Decision Date
Feb 24, 2010
Decision
SESE
Submission Type
Special
Regulation
21 CFR 862.1345
Device Class
Class 2
Attributes
Pediatric
Indications for Use
The EasyMax V Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. In addition, this device is not intended for the diagnosis of or screening for diabetes and not intended to be used in visually impaired users and neonates.
Device Story
EasyMax V SMBG System measures glucose in fresh capillary whole blood via test strips. System includes meter, test strips, and control solutions. Used by patients at home or healthcare professionals in clinical settings to monitor diabetes management. Input is capillary blood sample; meter performs electrochemical analysis to quantify glucose concentration. Output is numerical blood glucose value displayed to user. Results assist in evaluating diabetes control effectiveness. Not intended for diagnostic screening or use by visually impaired individuals or neonates.
Clinical Evidence
No clinical data provided. Substantial equivalence supported by design control activities, risk analysis, and verification/validation testing confirming that modifications did not alter fundamental scientific technology or intended use.
Technological Characteristics
Electrochemical glucose test system. Consists of a handheld meter, disposable test strips, and liquid control solutions. Operates via enzymatic reaction on test strip to generate electrical signal proportional to glucose concentration. Standalone device.
Indications for Use
Indicated for self-monitoring of blood glucose levels in patients with diabetes.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Related Devices
K100322 — TD-4277 BLOOD GLUCOSE MONITORING SYSTEM, MODEL 4277 · Taidoc Technology Corporation · Jun 28, 2010
K132072 — TRUE METRIX SELF-MONITORING BLOOD GLUCOSE SYSTEM, TRUE METRI PRO PROFESSIONAL MONITORING BLOOD GLUCOSE SYSTEM · Nipro Diagnostics, Inc. · Aug 15, 2013
K091481 — EASYPLUS MINI R13N SELF MONITORING BLOOD GLUCOSE SYSTEM · Eps Bio Technology Corp. · Aug 18, 2009
K070053 — EASYPLUS MINI SELF MONITORING GLUCOSE TEST SYSTEM, MODELS R1 AND R2 · Eps Bio Technology Corp. · Dec 3, 2007
K092887 — EASYPLUS MINI MASTERDRIVER SELF MONITORING BLOOD GLUCOSE SYSTEM, MODEL EPS09009 · Eps Bio Technology Corp. · Oct 21, 2009
Submission Summary (Full Text)
{0}
SPECIAL 510(k): Device Modification
OIVD Review Memorandum (Decision Making Document is Attached)
To: THE FILE
RE: DOCUMENT NUMBER: k092894
This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary):
1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.) EPS Bio Technology Corporation, EasyMax N Self Monitoring Blood Glucose System, Model: EPS08008 (k083099).
2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. This change was for:
A. Addition of speaking function to the meter but insufficient data was submitted to support use by visually impaired users.
B. The physical appearance of the meter has changed.
C. The trade name of the meter has changed.
D. The labeling was modified to reflect the changes to the device.
4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and performance characteristics.
5. A Design Control Activities Summary which includes:
a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
c) A declaration of conformity with design controls. The declaration of conformity should include:
i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.
6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices).
The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.